Johnston, Laura E. http://orcid.org/0009-0003-4948-0703
Randall, Jamie
Chouraichi, Safae
Luu, Mary http://orcid.org/0009-0003-8859-7488
Hunt, Allison L. http://orcid.org/0000-0002-2223-7944
Mauro, Lauren
Mueller, Claudius
Davis, Justin B.
Petricoin, Emanuel F.
Conrads, Thomas P. http://orcid.org/0000-0003-4742-3281
Cannon, Timothy L.
Huynh, Jasmine
Funding for this research was provided by:
Funding provided by philanthropic funds from Inova Schar Cancer Institute.
Article History
Received: 30 January 2024
Accepted: 29 August 2024
First Online: 14 September 2024
Competing interests
: T.P.C. is a ThermoFisher Scientific, Inc SAB member and receives research funding from AbbVie. E.F.P. is a SAB member and consultant to Ignite Proteomics, is on the editorial board of npjPO, and receives research funding from Genentech, Pfizer, Mirati, Springworks Therapeutics, Deciphera, AbbVie, and is a co-inventor of the RPPA technology described herein, and related HER2 biomarker patents and receives royalties on the related license agreements and is affiliated J.H. is on the advisory board for Exelixis Pharmaceuticals, Inc.